Exchange: NASDAQ·Updated 07:59 PM EDT
News
all
press releases
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.
Zacks
More News
Better Growth Buy: Axsome vs Revolution Medicines
Key PointsAxsome has a solid late-stage pipeline and growing commercialized drugs...
Nasdaq News: Markets
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
Key PointsRevolution Medicines has taken a new approach to the treatment of certain cancers...
Nasdaq News: Markets
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and commercial potential.
Zacks
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuation puts upcoming study results at the center of the next move.
Zacks
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
Tango Therapeutics enters a pivotal phase as vopimetostat drives its investment case, with 2026 clinical updates set to test its focused oncology pipeline.
Zacks
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.
Key PointsRevolution Medicines' cancer drugs in development could establish new standards of care in some niches...
Nasdaq News: Markets
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS G12D mutations.
Zacks
Can Revolution Medicines Be a Game-Changer Stock?
Key PointsRevolution Medicines' promising pancreatic cancer therapy could be approved later this year...
Nasdaq News: Markets
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.
Zacks
<
1
2
>

Advertisement|Remove ads.